Cancer, Bleeding Risks At The Heart Of Prasugrel Review; Could Limiting Use Help?
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA discusses labeling to restrict prasugrel use to one week or one month; less frequent dosing regimen would dampen sales projections.
You may also be interested in...
FDA’s Prasugrel Presentation To Advisory Committee Eases Doubts On Approvability
FDA presentation put the advisory committee at ease with prasugrel’s benefit-risk profile and may have turned the tide toward approvability.
Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.
FDA’s Prasugrel Presentation To Advisory Committee Eases Doubts On Approvability
FDA presentation put the advisory committee at ease with prasugrel’s benefit-risk profile and may have turned the tide toward approvability.